GE Healthcare Life Sciences continues to build out its flexible solutions across the cell therapy workflow with the commercial availability of SpinOculation C-Pro Protocol Software. Part of the Sepax™ C-Pro Cell Processing System, the software closes and automates the cell transduction step. When used in combination with the Sepax C-Pro instrument and CT-60.1 single-use kit, the software enables users to choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.

Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare Life Sciences, said: “Cell therapy manufacturing is complex and requires advanced technologies. GE Healthcare Life Sciences continues to invest and develop the digital solutions needed to advance cell and gene therapies. The SpinOculation C-Pro software application automates and simplifies a critical step in the cell therapy workflow and helps accelerate the development of next generation therapeutics.”

Additionally, the SpinOculation C-Pro Protocol helps users:

• Gain reproducibility in transduction steps with an automated and closed solution
• Save time in the manufacturing process by reducing manipulations
• Optimize transduction performance by adjusting open system parameters
• Simplify process validation by not using transduction enhancers

Marine De Lageneste, Development Engineer, R&D, Cell & Gene Therapy will answer questions at the Cell Therapy Manufacturing & Gene Therapy Congress for the poster titled “Closed and automated CAR-T cell lentiviral transduction by spinoculation.’’ The Congress takes place in Amsterdam, Netherlands from 3-6 December 2019.

The SpinOculation C-Pro application software is available worldwide.

About GE Healthcare Life Sciences

GE Healthcare Life Sciences helps therapy innovators, researchers and healthcare providers accelerate how precision diagnostics and therapies are invented, made and used. Our products enable biological analysis, research, development and the manufacture of advanced therapies and vaccines. Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Visit our website https://www.gelifesciences.com/about-us for more information.

GE Healthcare launched the Edison Developer Program to accelerate the adoption and impact of intelligent applications and developer services across health systems. The program is based on Edison, GE Healthcare’s secure intelligence platform, and helps healthcare providers gain easier access to market-ready algorithms and applications by directly integrating these technologies into existing workflows.

For developers, the Edison Developer Program offers a rich set of healthcare services to help accelerate their ability to build innovations that improve operational and clinical outcomes – and also gives them access to scale and the ability to deploy applications across GE Healthcare’s massive customer base. This program expands the existing Edison ecosystem of leading researchers, technology providers and academic institutions who develop, manage, secure and distribute advanced applications, services and AI algorithms to drive real healthcare outcomes.

GE Healthcare also unveiled several new, Edison-powered technologies, including smart devices and intelligent applications, across a variety of clinical areas. These new solutions are designed to make data, insights and clinical context more accessible and actionable across the health system, creating new value for providers and patients — from reducing costs and complexity to increasing the speed and accuracy of diagnosis.

“We introduced Edison just one year ago at RSNA to help health providers take advantage of data in new and significant ways,” said Kieran Murphy, President and CEO, GE Healthcare. “With the introduction of the Edison Developer Program, and a suite of new intelligent applications and smart devices powered by Edison, we are building on that promise as we continue to work with partners to realize our collective goal of advancing the future of health.”

New Edison Developer Program to Accelerate AI Integration, Advance Outcomes

Investment in healthcare startups is exploding– but implementing new innovations effectively can be cumbersome and complex, slowing adoption. For instance, deploying a one-off clinical AI application is currently a manual and disjointed process. Clinicians are looking for a single solution that can span multiple modalities and seamlessly integrate applications or AI algorithms directly into their existing workflows to harness the power of these technologies.

The Edison Developer Program addresses these needs directly by bringing market-ready AI applications to the Edison platform, integrating them into existing GE Healthcare offerings – on medical devices, in the cloud or at the edge of the network. This deep integration makes it easier for AI and analytics innovators to build, deploy and distribute their offerings. It breaks down barriers to adoption for clinicians, ultimately reducing costs and improving the value of new solutions.

GE Healthcare is actively working with a range of AI and analytics innovators – such as Arterys, iCAD, Koios Medical, MaxQ AI and Volpara– to deliver outcomes for healthcare systems via Edison. For example, Koios Medical built and deployed Breast Assistant, powered by Koios™DS, an embedded application designed to automatically provide an AI-based quantitative risk assessment that aligns to a BI-RADS category, delivering results in two seconds or less and providing decision support for the clinician. Together, Koios and GE Healthcare integrated their solution into the LOGIQ E10 ultrasound system. Also as part of the Edison Developer Program, GE Healthcare recently launched two initiatives in India and China aimed at growing the regional ecosystem and accelerating availability of local solutions.

“The opportunities for healthcare with a truly intelligent connected digital enterprise are significant, but no one organization can get there alone,” said Amit Phadnis, Chief Digital Officer, GE Healthcare. “The Edison Developer Program is unique in its deep technology integration and scaling through the workflow, opening the door to faster adoption by health systems. Bringing together leading technology providers, developers and academic institutions under a single, connected ecosystem will help our customers simplify and optimize data aggregation and orchestration of clinical and operational applications in ways that have the potential to create real impact from the bottom line to better patient outcomes.”

The Edison Developer Program exposes a number of potential capabilities of the Edison platform, including secure device connectivity, data aggregation for clinical context, advanced visualization, workflow and AI orchestration, in addition to a rich set of AI capabilities for data traceability, curation, annotation, model training and inferencing. This set of services will reduce the complexity of developing and integrating AI and data-based healthcare applications in clinical workflows. Program members are selected and vetted based on rigorous clinical and technical evaluations as well as regulatory clearance to ensure confidence and security of solutions offered through the Edison platform.

Expanded Partner Network to Extend Rapidly Growing Edison Ecosystem

These AI and analytics startups add to a rapidly growing Edison ecosystem of prominent academic institutions, technology providers and medtech companies, including:

• Partners HealthCare and GE Healthcare are working together to improve the patient journey through co-development and integration of deep learning technology across the entire continuum of care under the Massachusetts General Hospital and Brigham and Women’s Hospital Center for Clinical Data Science. The collaboration currently includes 15 active projects underway within areas such as Women’s Health, Cardiology, Oncology, Hospital Operations and Emergency Medicine, and relevant imaging modalities such as Computed Tomography (CT), Magnetic Resonance (MR) and Ultrasound (US).
• The Saint-Joseph Hospital Foundation in Paris and GE Healthcare are creating a research and development laboratory designed to further the benefits of digital technologies across the healthcare journey, including the use of data and AI to optimize operating theatres and monitor the impact of contrast media.
• Intel and GE Healthcare have integrated the open source Intel Distribution of OpenVINO toolkit software in the Edison platform for inference acceleration across modalities from edge to cloud. This has resulted in break through performance in Artificial Intelligence Prescription (AIR x), an automated workflow tool designed to accelerate and optimize MR brain scanning, and the Critical Care Suite pneumothorax detection algorithm running on GE Healthcare’s Optima* XR240amx mobile X-ray system, all powered by Intel processors.

New Edison Devices, Applications to Improve Efficiencies, Clinical Diagnosis

Additionally, GE Healthcare unveiled a number of new Edison-powered smart devices and intelligent applications designed to help healthcare providers simplify workflows and increase efficiencies while also improving patient comfort and advancing clinical outcomes. These offerings bring together GE Healthcare’s unique capabilities across both imaging devices and software to help health systems more quickly and seamlessly deploy technologies across their care environments.

• Edison Open AI Orchestrator: Designed to orchestrate AI at scale for imaging workflows, the new Edison Open AI Orchestrator simplifies the implementation, deployment, support and scaling of multiple AI applications including from partners iCAD and MaxQ AI. Designed to seamlessly integrate clinical applications into the radiology PACS reading workflow, this offering reduces the complexity of multiple systems and algorithms working together that could lead to error and risk if implemented incorrectly.
• LOGIQ E10: This next-generation radiology ultrasound system integrates AI, advanced tools and enhanced workflow capabilities to enable clinicians to scan, diagnose and treat a wide range of patients across a broad spectrum of conditions. One of its newest applications, Breast Assistant, powered by Koios DS, automatically provides an AI-based quantitative risk assessment that aligns to a BI-RADS category. The results are available in two seconds or less, providing decision support for the clinician and helping improve consistency across the department.
• New Revolution family CT scanner: This powerful, high performing and reliable CT simplifies every step of the CT workflow. Powered by AI, the new Revolution family CT scanner uses real-time depth sensing technology to generate a 3D model of a patient’s body to pinpoint the center of the scan range and automatically align it to the isocenter of the bore. Altogether, it is designed to simplify, streamline and automate the entire CT experience.
• AIR x: An Edison application, this AI-based, automated workflow tool for MRI brain scanning increases consistency and productivity by providing automated slice prescriptions to help reduce previously redundant, manual steps. AIR x produces images that have less variability between technologists and between scans, to lower the chances for a patient to be recalled due to incorrect slice placement. An increase inconsistency is particularly important when doing longitudinal assessments for diseases like Alzheimer’s and Multiple Sclerosis. Technologists can set up exams five times faster and perform four times fewer mouse clicks using deep learning with AIR x.

The Edison platform helps GE Healthcare and select strategic partners design, develop, manage, secure and distribute applications and AI algorithms quickly. These new Edison-enabled devices and applications support GE Healthcare’s goal of advancing the future of health and continue the growing strength of the Edison ecosystem. Additional details can be found at here and at RSNA in GE Healthcare’s booth in the South Hall #4133 or in the AI Showcase Level 1 North #10905.

EOS imaging  a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, announced the launch of its new generation imaging system, EOSedge,in Europe, Canada and Australia.The Company will unveil its new system at the upcoming Radiological Society of North America (RSNA) 2019 Annual Meeting starting onDecember1st.

EOSedge combines the latest technological innovations in X-ray detection, low-dose radiation and high image resolution,to deliver outstanding musculoskeletal imaging exams. The system incorporates new Flex Dose™ technology to modulate radiation dose along the patient’s body as well as high-resolution photon counting detection to provide optimal image quality for musculoskeletal radiography.

EOSedgeis also designed to improve patient comfort and maximize throughput.Its new open cabin includes a motorized, enlarged patient platform which enables easy access to a broader range of patients, and faster patient positioning,in addition to delivering larger fields of examination.In line with the Company’s dedication to more informed diagnostic imaging, EOSedge provides local and full body, weight-bearing, low-dose biplanar exams of adult and pediatric patients, allowing for unbiased images and precise anatomical data of patients in functional positions.

EOSedge will strengthen the portfolio of the Company, with the first-generation EOS® system continuing to be part of the EOS imaging offering. Both EOSedge and EOS are designed to work seamlessly with EOS Advanced Orthopedic Solutions, including3DServices, EOSapps 3D surgical planning for spine, hip and knee as well as EOSlink™, which delivers the EOS surgical plan into the operating room to be used with advanced surgical technologies.

EOSedge has received regulatory approvals in Europe (CE Mark), Canada (Health Canada) and Australia(TGA)and is the subject of a pending 510(k) review by the U.S. Food and Drug Administration (FDA).

The first EOSedgesystem was installed earlier this year at the Imagerie Médicale du Créqui, in Lyon, France. Dr. Olivier Fantino, Musculoskeletal Radiologist at Imagerie Médicale du Parc and Imagerie Médicale du Créqui, commented:”We have been using thefirst-generationEOS system since 2011, and this unique orthopedic imaging system has allowed us to develop our practice, serving our referring

clinicians with better, more informed exams.EOSedge is a leap forward in image quality, both in terms of spatial resolution and image contrast, all with a low radiation dose. Our months of utilization in routine have also proven enhanced patient comfort, facilitated system operation and a strong reduction of exam time. We are thrilled with our experience of EOSedgeand expect it to open up new fields of application use in musculoskeletal imaging”.

“We engineered EOSedgeto equip both radiologists and orthopedic surgeons with a best-in-class imaging system that combines the latest innovations to provide high quality diagnostic capabilities of orthopedic conditions at a low dose. Images and data obtained with EOSedgewill further fuel our Advanced Orthopedic Solutions, while addressing a broad range of imaging and orthopedic surgery challenges. This breakthrough in orthopedic imaging is the result of a multi-year development effort by our outstanding inter-disciplinary team. Unveiling EOSedge at RSNA, the largest global imaging convention, will mark another pivotal step in realizing our strategic vision to deliver the best end-to-end solutions in orthopedic care,” stated Mike Lobinsky, Chief Executive Officer of EOS imaging

ABOUT EOS imaging

EOS imaging is a global medical device company that designs, develops and markets innovative, low dose 2D/3D full body and weight-bearing imaging, rapid 3D modeling of EOS patient X-ray images, web-based patient-specific surgical planning, and integration of surgical plan into the operating room that collectively bridge the entire spectrum of care from imaging to post-operative assessment capabilities for orthopedic surgery. With a primary focus on hips, knees, and spine, EOS imaging is targeting a $2 billion annual market opportunity. EOS imaging has over 350 systems installations in more than 30 countries generating more than 1 million patient exams annually. EOS imaging has corporate locations in U.S., France, Canada, Germany, and Singapore, and engages more than 175 employees. For additional information, please visit www.eos-imaging.com.

The 2nd Edition Africa Healthcare Extension Summit and Africa Women’s Health Summit launches in Nairobi, Kenya, the leading event is organized by Verve Management UAE, and will be held over two days with participation of government officials from Ministries of Health across Africa, Regulatory Bodies, Healthcare Associations, stakeholders, Doctors, Obstetricians, Gynaecologists, Reproductive Medicine Specialists, Infertility Specialists and all other Medical Professionals.

AHES and AWHS is under the patronage of Ministries of Health Malawi, Zambia, Lesotho, Zimbabwe, Eswatini and being supported by Africa Healthcare Federation, Kenya Healthcare Federation and many more!

Key topics were discussed by industry professionals during the AHES sessions which included Role of Innovation in Augmenting healthcare, Healthcare Financing Systems in Africa, Alternative Forms of Healthcare Partnerships, Medical Devices Management Policy, Innovations & Changes in Cancer Therapy and Improving patient safety & quality in healthcare.

“In healthcare, business as usual is not good enough, it will not achieve the goals we have set ourselves. So, we need innovation. But what is innovation exactly and how do we ensure that healthcare innovations have impact? I will be exploring these issues using my experience towards achieving a global impact in the treatment of diarrhoea in children.” says, Simon Berry of ColaLife.

“Very informative and networked conference that brings decision makers and projects together. An excellent opportunity for participants to understand key healthcare issues in the region while meeting key policy and decision makers.” says, Salim Hasham of Health Services International.

AWHS topics includes Interventions in Obesity Management for Women, Current trends in the treatment of Polycrystic Ovary Syndrome, Understanding Endometriosis, Stem cells and other cell-based therapies. AWHS 2019 Eminent Speakers includes: Dr. Maureen Owiti (Kenyatta National Hospital), Dr. Navin Chander Raina (M.P. Shah Hospital), Dr. Elizabeth Gitau (Kenya Medical Association), Dr. Elizabeth Nakiyingi (Women’s Hospital International and Fertility Centre) and many more!

AHES and AWHS 2019 is also grateful to this year’s sponsors: Varian Medical Systems, Vezeeta, Adwia, Boston Scientific, Renata Limited and Sukraa Software Solution.

About Verve Management:
Verve Management is UAE’s business facilitating platform that connects people, partners and ideas. Verve Management delivers remarkable events and provide solutions through Congresses & Summits, Trainings & Workshops, Exhibitions, Association Management, Industry Meetings and Managed Events in Asia, Middle East and Africa.

Signant Health announced that it has joined the non-profit Association of Clinical Research Organizations (ACRO). ACRO, a global coalition of research and technology companies, makes it their mission to advocate as the collective voice of the innovative clinical research industry to regulators and policymakers, educating stakeholders and shaping policies that foster efficient, effective and safe conduct of clinical research.

Founded in 2002, ACRO supports members by elevating their positions and goals to legislators, ensuring regulators such as the FDA, NIH, EMA, and lawmakers understand the nuances and intricacies faced by clinical trial organizations. This work influenced some of the more important recent clinical trial regulations such as the 21st Century Cures Act and EU Clinical Trial Regulation.

As the 13th member company elected into ACRO, Signant Health joins as one of the industry’s premier eCOA, eConsent, and clinical trial technology companies.

Mike Nolte, CEO of Signant Health, said “As a technology provider, Signant brings a unique perspective to ACRO, promoting collaboration across the industry to achieve our shared responsibility for advancing patient-centric clinical research. Aligned with our strategy and values, ACRO has prioritized conversations around patient safety, privacy, and technology’s impact on clinical trials, and we are excited to join with ACRO and its member companies to support policy and investment that ensure safe and efficient trials for patients everywhere.”

“Signant Health’s mission – ensuring the patient remains at the forefront of clinical trial design and execution, while advancing the efficiency of the clinical trial enterprise – is one shared by the member companies of ACRO,” said Executive Director, Doug Peddicord. “We are extremely pleased to welcome Signant as our newest member and look forward to working together to move our industry forward.”

To learn more about Signant Health visit https://signanthealth.com/. For further information on ACRO, please visit https://www.acrohealth.org/.

Who Is Signant Health?

The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable hundreds of sponsors and CROs (including all Top 20 pharma) to extend the reach of drug development, expand patient opportunities and improve data quality – helping them bring life-changing therapies to our families and communities around the world. Take a significant step toward patient-centricity at signanthealth.com.